Phase 1 Other Solid Tumors Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Breast CancerOvarian CancerColorectal Carcinoma+4 more
AstraZeneca45 enrolled18 locationsNCT05877599
Recruiting
Phase 1Phase 2
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Colorectal, CancerCutaneous MelanomaOther Solid Tumors+1 more
IDEAYA Biosciences336 enrolled15 locationsNCT03947385
Recruiting
Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
Biliary Tract CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
SystImmune Inc.160 enrolled17 locationsNCT07021066
Recruiting
Phase 1
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Prostate CancerEwing SarcomaOther Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.110 enrolled3 locationsNCT06926283
Recruiting
Phase 1
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Other Solid TumorsLocally Advanced or Metastatic Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd.26 enrolled1 locationNCT05631964
Recruiting
Phase 1Phase 2
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316
Recruiting
Phase 1Phase 2
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Cervical CancerProstate CancerUrothelial Carcinoma+5 more
Evopoint Biosciences Inc.204 enrolled1 locationNCT06022757